to enhance national security and the public health by modernizing influenza vaccines and technologies.
This expanded collaboration with Sanofi is BARDA’s second program to focus on developing a novel coronavirus vaccine candidate in the past few weeks. There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration has issued an emergency use authorization to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.
BARDA also is working with counterparts across the government, including within HHS and with the Department of Defense. The team is reviewing potential vaccines, treatments and diagnostics from across the public and private sectors, particularly products in development for Middle East Respiratory Syndrome or Severe Acute Respiratory Syndrome , to identify promising candidates for development and licensure to detect, protect against or treat novel coronavirus infections.
To obtain information about any potential products in development in the private sector that could be used in responding to the novel coronavirus outbreak, the U.S. government launched a single point-of-entryfor innovators and product developers to submit brief descriptions of their diagnostics, therapeutics, vaccines, and other products or technologies relevant to this new virus.
Federal agencies are particularly interested in identifying products and technologies that have progressed into or beyond non-clinical studies, have established large-scale commercial Good Manufacturing Practices manufacturing capability, and/or have utilized a platform already approved by the U.S. Food and Drug Administration .
PHEgov Fix the HHS website!
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: Reuters - 🏆 2. / 97 Read more »